First Tracks Biotherapeutics, Inc. TRAX
$17.05
▲ +3.58% 24H
About
First Tracks Biotherapeutics is a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways to treat autoimmune and inflammatory diseases. The company's pipeline includes three initial assets: ANB033, a CD122 antagonist in Phase 1b trials for celiac disease and eosinophilic eso…
SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees104
TickerTRAX
Statistics
Market Cap$592.5M
Revenue (TTM)$0
Net Income-$163.7M
Net Margin—
EPS—
P/E—
P/S—
P/B2.31
EV/EBITDA-1.71
ROE-41.8%
Dividend Yield—
Price$17.05
Data: Twelve Data · Revenue = mcap / P/S